中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

299 records (took 0.026 seconds)

    ORGANIC COMPOUNDS
    132.
    发明申请
    ORGANIC COMPOUNDS 有权

    公开(公告)号：US20220008423A1

    公开(公告)日：2022-01-13

    申请号：US17379399

    申请日：2021-07-19

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Wei YAO ,  Peng LI

    IPC: A61K31/519 ,  C07D471/14 ,  A61P25/28 ,  A61K31/4985 ,  A61K45/06 ,  A61P25/00 ,  A61P25/18 ,  A61P25/24

    Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

    NOVEL USES
    133.
    发明申请
    NOVEL USES 有权

    公开(公告)号：US20210379072A1

    公开(公告)日：2021-12-09

    申请号：US17287478

    申请日：2019-10-21

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Robert E. DAVIS ,  Kimberly E. VANOVER

    IPC: A61K31/519 ,  A61P25/16

    Abstract: The disclosure provides methods, treatments and materials for treating diseases or disorders associated with the dopamine D1 receptor intracellular pathway. In particular, the present disclosure provides for methods of treating such diseases and disorders in combination with a dopamine replacement therapy.

    NOVEL COMPOSITIONS AND METHODS
    134.
    发明申请
    NOVEL COMPOSITIONS AND METHODS 有权

    公开(公告)号：US20210361648A1

    公开(公告)日：2021-11-25

    申请号：US17338573

    申请日：2021-06-03

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Peng LI ,  Wei YAO ,  Robert DAVIS

    IPC: A61K31/4985 ,  A61K9/06 ,  A61K9/00

    Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

    ORGANIC COMPOUNDS
    136.
    发明申请
    ORGANIC COMPOUNDS 有权

    公开(公告)号：US20210205310A1

    公开(公告)日：2021-07-08

    申请号：US17059160

    申请日：2019-05-24

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Lawrence P. WENNOGLE ,  Joseph HENDRICK ,  Robert DAVIS

    IPC: A61K31/519 ,  A61P35/00

    Abstract: The disclosure relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of certain cancers or tumors, such as gliomas. In another embodiment, the disclosure relates to the combination of inhibitors of PDE1 and an antitumor agent for the treatment of certain cancers or tumors, such as gliomas.

    NOVEL METHODS
    139.
    发明申请
    NOVEL METHODS 有权

    公开(公告)号：US20210093634A1

    公开(公告)日：2021-04-01

    申请号：US17115416

    申请日：2020-12-08

    Applicant: INTRA-CELLULAR THERAPIES, INC.

    Inventor： Gretchen SNYDER ,  Robert DAVIS ,  Lawrence P. WENNOGLE

    IPC: A61K31/4985 ,  A61P25/22 ,  A61P25/24

    Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A/mu-opioid receptor or 5-HT2A/D1 and/or D2/mu-opioid receptor ligand.

Patent Agency Ranking